NanoViricides Inc. (NNVC)

[arvitar]

How will yet another PR about Moffat's results change the fact that NNVC doesn't have enough money to continue current operations for more than another year?

The Company has an accumulated deficit at March 31, 2017 of $72,570,721. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of March 31, 2017 the Company had cash and cash equivalents of $16,155,085.

p.9 http://www.ih.advfn.com/p.php?pid=nmona&article=74594460